

April 26, 2017



## Moleculin Biotech to Present at Joseph Gunnar & Co. PIONEERS 2017 Conference

HOUSTON, TX -- (Marketwired) -- 04/26/17 -- Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced that Walter Klemp, Chairman and CEO, will present a corporate overview at Joseph Gunnar & Co.'s PIONEERS 2017 conference. The investment conference will be held at the Mandarin Oriental Hotel in New York City on Tuesday, May 2, 2017 and the Moleculin presentation will start at 2:30 pm ET. Mr. Klemp will also participate in one-on-one investor meetings during the conference.

The presentation will be webcast live at <http://wsw.com/webcast/pioneers2/mbrx>, and available for replay at: [www.moleculin.com](http://www.moleculin.com).

For more information about the conference or to schedule a one-on-one meeting with Moleculin please contact your Joseph Gunnar & Co. representative or e-mail [conference@jgunnar.com](mailto:conference@jgunnar.com).

### ***About Moleculin Biotech, Inc.***

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

For more information about the offering, please visit <http://www.moleculin.com>.

### ***Forward-Looking Statements***

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology

including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our Form 10-K for year ended December 31, 2016 filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contact

PCG Advisory Group

Kirin Smith

Chief Operating Officer

D: 646.863.6519

E: [ksmith@pcgadvisory.com](mailto:ksmith@pcgadvisory.com)

Source: Moleculin Biotech, Inc.